Pfizer’s COVID-19 vaccine trial data shows long-term efficacy

Pfizer’s COVID-19 vaccine
Pfizer said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.



from latest-news - SUCH TV https://ift.tt/3FFnxyl

Comments

Popular posts from this blog

Low payments by fed govt hampered development in Sindh, CM Murad tells Bilawal Bhutto

North Korea imported Chinese masks before declaring Covid victory

Country’s economy has stabilized owing to prudent policies, Asad Qaiser

President Ashraf Ghani launches Afghanistan's coronavirus vaccine campaign

Taliban declare war in Afghanistan over, call for peaceful relations with world

Sanctions could cause space station to crash: Roscosmos

Sindh govt seeks army's help in implementation of coronavirus SOPs

FM Qureshi contact with UN Secretary General to discuss regional, global issues

Pakistan Army continued its relief and rescue operation in Karachi: ISPR

Monsoon rains add to Karachi’s woes, kill two youngsters